Barrington analyst Michael Petusky maintained a Buy rating on Lemaitre Vascular today and set a price target of $95.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Petusky has given his Buy rating due to a combination of factors including LeMaitre Vascular’s strong financial performance and promising growth prospects. The company reported a notable 12% organic revenue growth in the third quarter, driven by significant increases in sales of grafts and shunts, and a successful international launch of Artegraft. Additionally, LeMaitre’s adjusted earnings per share exceeded expectations, reflecting robust operational efficiency.
Furthermore, the company’s financial health is underscored by a strong balance sheet, with substantial cash reserves and impressive free cash flow generation. Petusky also highlights the company’s ability to maintain double-digit organic growth and margin expansion, which justifies the premium valuation. With a price target of $95, Petusky maintains an OUTPERFORM rating, indicating confidence in LeMaitre’s continued success and potential for further stock price appreciation.
In another report released today, Lake Street also reiterated a Buy rating on the stock with a $110.00 price target.
Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LMAT in relation to earlier this year.